DUBLIN--(BUSINESS WIRE)--The "Diabetic Retinopathy Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
The global diabetic retinopathy market is currently witnessing strong growth. Looking forward, the market is projected to register a CAGR of around 7% during 2020-2025.
The increasing prevalence of diabetes, along with the growing geriatric population across the globe, represent as the key factors driving the growth of the market. Furthermore, the rising incidence of blindness caused by DR is also providing a boost to the market growth.
There is an increasing awareness among the masses regarding the available treatment alternatives and the benefits of early detection of DR. This has resulted in the widespread adoption of technologically advanced procedures and equipment, such as the improved ophthalmic diagnostic and surgical instruments. These procedures and equipment enable early detection and efficient treatment of the ailment with higher precision and minimal discomfort to the patient.
Other factors, including the increasing healthcare expenditures, the implementation of favorable government policies to make advanced healthcare services available to the masses and extensive research and development (R&D) activities, are projected to drive the market further.
The competitive landscape of the industry has also been examined with some of the key players being Alimera Sciences, Allergan PLC, Ampio Pharmaceuticals, Bayer Healthcare, BCN Peptides, Genentech, Kowa Group, Novartis AG, Regeneron Pharmaceuticals Inc., Sirnaomics Inc., etc.
Key Questions Answered
- How has the global diabetic retinopathy market performed so far and how will it perform in the coming years?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the treatment type?
- What is the breakup of the market based on the end-user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global diabetic retinopathy market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered
2 Scope and Methodology
3 Executive Summary
4.2 Key Industry Trends
5 Global Diabetic Retinopathy Market
5.1 Market Overview
5.2 Market Performance
5.3 Market Forecast
6 Market Breakup by Type
6.1 Proliferative Diabetic Retinopathy
6.2 Non-proliferative Retinopathy
7 Market Breakup by Treatment Type
7.1 Anti VEGF Drugs
7.2 Steroid Implants
7.3 Laser Surgeries
8 Market Breakup by End-user
8.1 Hospitals and Pharmacies
8.2 Eye Clinics
8.3 Ambulatory Surgical Centers (ASCs)
9 Market Breakup by Region
9.1 North America
9.4 Latin America
9.5 Middle East & Africa
10 SWOT Analysis
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Competitive Landscape
13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- Alimera Sciences
- Allergan PLC
- Ampio Pharmaceuticals
- Bayer Healthcare
- BCN Peptides
- Kowa Group
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Sirnaomics Inc.
For more information about this report visit https://www.researchandmarkets.com/r/17ob1d